Clinical Trial Update: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy study of peginterferon beta-1a in relapsing multiple sclerosis completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Plegridy (peginterferon beta-1a) (peginterferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2017-01-13